Endo Pharmaceuticals (NASDAQ:ENDP)
| CAPS Rating |
|
|---|---|
| Open | $35.12 |
| Previous Close | $35.37 |
| Daily Range | $34.70 - $35.60 |
| 52-Week Range | $26.02 - $44.53 |
| Market Cap | $4.10B |
| P/E Ratio | 13.70 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 1,292,611 |
| Average Daily Volume | 0 |
ENDP
VS S&P 500 (SPY)
How do you think ENDP will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ENDP Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ENDP News and Commentary
- Pfizer Recalls Birth Control Pills - Analyst Blog – NASDAQ
- Risk-Reward Balances for Endo Pharma - Analyst Blog – NASDAQ
- Risk-Reward Balances for Endo Pharma - Analyst Blog – NASDAQ
- Risk-Reward Balances for Endo Pharma - Analyst Blog – NASDAQ
- Zacks.com featured expert Kevin Matras highlights: Akorn, Inc., Diana Shipping Inc., Endo Pharmaceut – NASDAQ
- 1 Reason the Street Should Expect Big Things From Endo Pharmaceuticals Holdings – The Motley Fool
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- Why Endo Pharmaceuticals' Earnings Are Outstanding – The Motley Fool
- Good News for Endo Pharma - Analyst Blog – NASDAQ
- Company News for December 13, 2011 - Corporate Summary – NASDAQ
- Mid-Day Update: Stocks Lower as Europe Concern Weighs; Moody's Evaluate Europe Ratings in 2012 – NASDAQ
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- Mid-Day Update: Stocks Firm as Greece Referendum Proceeds; Jobs Gain More Than Expected – NASDAQ
- Registration Effectiveness Orders Issued By The SEC – SmartMoney
- Endo Pharmaceuticals Earnings Preview – The Motley Fool
- Checking the Quality of Hospira's Growth – The Motley Fool
- Let's Check the Quality of Jazz Pharmaceuticals' Growth – The Motley Fool
- About That Developing Technology... – The Motley Fool
- 5-Star Stocks Poised to Pop: Endo Pharmaceuticals – The Motley Fool
- Why the Future Looks Bright for Endo Pharmaceuticals – The Motley Fool
RSS Headlines
Fool UK
